The new information generated over the last decade on the physiology/pharmacology of the normal bladder and on the pathophysiology of the overactive bladder has resulted in the introduction of a new therapeutic principle, β3-adrenoceptor (AR) agonism, and the approval of mirabegron, a selective agonist at β3-ARs.
It may be asked in what respects the β3-AR agonists as a group, and mirabegron in particular, differ from the antimuscarinics, and what can clinically be gained by the β3-AR agonists. In this short review, the mechanisms of action, clinical efficacy, and adverse effect profiles of the two groups of drugs are compared and discussed.
Written by:
Andersson KE. Are you the author?
Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA.
Reference: Curr Urol Rep. 2013 May 16. Epub ahead of print.
doi: 10.1007/s11934-013-0335-8
PubMed Abstract
PMID: 23677692
UroToday.com Overactive Bladder (OAB) Section
